About Cannevert Therapeutics
Cannevert Therapeutics is a Healthcare company based in Vancouver (Canada) founded in 2014, and was acquired by Veritas Pharma in April 2017. Investigating the therapeutic potential of different cannabis cultivars to treat pain, nausea, depression and anxiety. Its chief executive, as recorded, is Lui Franciosi. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Diversified.
Company details
Cannevert Therapeutics was founded in 2014 in Vancouver, Canada, to examine cannabis cultivars scientifically for medical applications. Research focuses on chemical profiling of extracts using analytical methods, including heat-processed versions, followed by animal testing for efficacy against chronic conditions like pain, nausea, depression, and anxiety in cancer or AIDS patients. A partnership with Veritas Pharma was established, and an exemption from Health Canada for cannabis studies was obtained in 2016.
- Headquarters Vancouver, Canada
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cannevert.com
- Acquired by Veritas Pharma (Apr 2017)
- Investors
- Acquired byVeritas Pharma
(Apr 2017)
Investors in Cannevert Therapeutics
Cannevert Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Veritas Pharma Inc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Veritas Pharma is a discovery company focused on developing new medicinal cannabis cultivars for specific diseases. | 2013 | veritaspharmainc.com | Vancouver, Canada |
Investor details for Cannevert Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cannevert Therapeutics
1 people are tracked at Cannevert Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Lui Franciosi | CEO | Leadership |
Complete people profiles for Cannevert Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cannevert Therapeutics
2 dated milestones of Cannevert Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Cannevert Therapeutics is founded.
- Exit Acquired by Veritas Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cannevert Therapeutics
Complete news archive for Cannevert Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cannevert Therapeutics
Cannevert Therapeutics was founded in 2014.
Cannevert Therapeutics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Lui Franciosi is the CEO of Cannevert Therapeutics, as recorded in our data.
Cannevert Therapeutics was founded in 2014 in Vancouver, Canada, to examine cannabis cultivars scientifically for medical applications. Research focuses on chemical profiling of extracts using analytical methods, including heat-processed versions, followed by animal testing for efficacy against chronic conditions like pain, nausea, depression, and anxiety in cancer or AIDS patients. A partnership with Veritas Pharma was established, and an exemption from Health Canada for cannabis studies was obtained in 2016.
Cannevert Therapeutics has 1 investor. Key investors include Veritas Pharma Inc.
Yes. Cannevert Therapeutics was acquired by Veritas Pharma in April 2017.